ACCELERATED PUBLICATION
Pex19p Dampens the p19ARF-p53-p21WAF1 Tumor Suppressor Pathway*

Takashi SugiharaDagger , Sunil C. Kaul§, Jun-ya Kato, Roger R. Reddel||, Hitoshi NomuraDagger , and Renu WadhwaDagger **

From the Dagger  Chugai Research Institute for Molecular Medicine, 153-2 Nagai, Niihari-Mura, Ibaraki 300-41, Japan, the § Institute of Molecular and Cell Biology, National Institute of Advanced Industrial Science and Technology (AIST), 1-1 Higashi, Tsukuba, Ibaraki 305-8566, Japan, the  Graduate School of Biological Sciences, Nara Institute of Science and Technology, 8916-5 Takayama, Ikoma, Nara 630-0101, Japan, and the || Children's Medical Research Institute, Westmead, New South Wales 2145, Australia

Received for publication, January 11, 2001, and in revised form, March 1, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

We isolated a 33-kDa protein, Pex19p/HK33/HsPXF, as a p19ARF-binding protein in a yeast two-hybrid screen. We demonstrate here that Pex19p interacts with p19ARF in the cell cytoplasm and excludes p19ARF from the nucleus, leading to a concurrent inactivation of p53 function. Down-regulation of Pex19p by its antisense expression resulted in increased levels of p19ARF, increased p53 function, and a p53/p21WAF1-mediated senescence-like cell cycle arrest. The data demonstrated a novel mechanism of down-regulation of the p19ARF-p53 pathway.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

The INK4a (MTS1, CDKN2) locus on chromosome 9p21 is frequently altered in human cancers. It encodes two unrelated tumor suppressor proteins: p16INK4a, an inhibitor of the cyclin D-dependent kinases that acts upstream of pRb, and p19ARF, an alternative reading frame protein that acts upstream of p53 (1-3). Both of these proteins have roles in replicative senescence and ras-induced premature senescence of primary cells (4-7). Analysis of p19ARF knock-out mice suggested that this protein functions as a tumor suppressor (3, 8, 9). Recently, it has been shown that p19ARF acts by obstructing degradation and transcriptional silencing of p53 by mdm2 (10, 11). It retains Mdm2 in the nucleolus, preventing its export to the cytoplasm, which is required for mdm2-mediated p53 degradation (12-16). Because p19ARF shares no amino acid homology with known proteins and lacks any decisive functional protein motifs, other cellular factors that might regulate its activity and thereby its execution of growth arrest via the p19ARF-p53 pathway remain poorly defined. Using a yeast interactive screen, we have identified the farnesylated protein Pex19p/HK33/HsPXF (essential for peroxisomal biogenesis) (17-19) as a p19ARF-binding protein. In the present study, we report that the two proteins interact in the cell cytoplasm leading to exclusion of p19ARF from the nucleus and inactivation of p53 function, which constitutes a novel mechanism of down-regulation of the p19ARF-p53 pathway. Neutralization of the Pex19p function by its antisense expression led to an accelerated activation of p19ARF function and p53-p21WAF1-mediated cell cycle arrest that resembled cellular senescence.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

Yeast Two-hybrid Screen-- cDNAs encoding full-length p19ARF (p19ARF-F), amino-terminal 80 amino acids (p19ARF-N) and carboxyl-terminal 89 amino acids (p19ARF-C) were cloned into the BamHI, SalI site of the yeast expression vector pODB8 (a kind gift from O. Louvet) (20). For library screening the yeast reporter strain PJ69/2A (Trp-/Leu-/His-) was sequentially transformed with the plasmid pODB8/p19ARF and a human testis cDNA library (CLONTECH) according to the manufacturer's protocol. The cDNA-derived plasmids were recovered from yeast and reintroduced into the yeast reporter strain Y187 to confirm specificity of the interactions. To determine beta -galactosidase activity in yeast, five colonies of simultaneously transformed Y187 yeast cells were grown overnight in Leu-/Trp- plates. Cell extracts were prepared using standard conditions, and enzyme activity was determined using the GAL-Tropix kit according to the manufacturer's protocol (Tropix Inc.). The clones were sequenced using an ABI sequencer (PerkinElmer Life Sciences).

Cell Culture and Transfections-- Mouse embryonic fibroblasts and monkey kidney cells were cultured in Dulbecco's modified Eagle's minimal essential medium supplemented with 10% fetal bovine serum. Transfections were performed using LipofectAMINETM (Life Technologies, Inc.). Typically, 1 µg of plasmid DNA was used per well of a 24-well dish, and 3 µg was used per 6-cm dish.

Plasmid Constructions-- Full-length Pex19p was cloned from mouse testis by reverse transcription-polymerase chain reaction using sense (5'-gaa ttc atg gcg gct gct gag gaa ggt-3') and antisense (5'-gtc gac tca cat gat cag aca ctg ttc-3') primers with EcoRI and SalI sites, respectively. Polymerase chain reaction amplification product (94 °C for 30 s, 55 °C for 30 s, and 72 °C for 3 min) was purified and sequentially ligated to pGEM-T Easy (Promega), pEGFPC1 (CLONTECH), and pcDNA4/HisMax (Invitrogen) vectors. Mouse p19ARF and its deletion mutants were cloned into the indicated vectors by a similar strategy. The integrity of the plasmids was confirmed by sequencing.

Mammalian Two-hybrid Analysis-- COS-7 cells were seeded at 50-60% confluence in 24-well plates and transfected with 1 µg of DNA containing pG5 reporter plasmid, pM/mHK33, VP16/p19ARF, and pM or VP16 control vectors as indicated in the relevant figure legends. After 3 h of transfections, cells were refed with fresh medium and then lysed in universal lysis buffer (Promega) after 48 h. Luciferase activity was measured using the Dual-LuciferaseTM reporter assay system (Promega). The results presented are the means of at least three transfections.

In Vivo Coimmunoprecipitation-- Cell lysates (400 µg of protein) in 400 µl of Nonidet P-40 lysis buffer were incubated at 4 °C for 1-2 h with an antibody used for immunoprecipitation, as indicated in figure legends. Immunocomplexes were separated by incubation with protein A/G-Sepharose, Western blotting was performed with the indicated antibodies by standard procedures, and detection was done using ECL chemiluminescence.

Reporter Assays-- NIH 3T3, NIH-ARF, NIH-ARF/pcDNA4-HisMAX- Pex19p (sense), and NIH-ARF/pcDNA4-HisMAX-Pex19p (antisense) derivatives (selected in 1 mg/ml zeocine, Invitrogen) were transfected with the p53-responsive luciferase reporter plasmid, PG-13luc (kindly provided by Dr. Bert Vogelstein). As a control, pRL-TK vector (Promega) was co-transfected in each assay to correct for variations in transfection efficiency. Cells were lysed and measured for luciferase activity as described above.

    RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

To isolate p19ARF interacting proteins, a Gal4BD (Gal4 binding domain)-p19ARF fusion protein was used as a bait to screen a library of human cDNAs cloned into a Gal4AD (activation domain) yeast two-hybrid plasmid. One of the five clones isolated was strongly positive as determined by His prototrophy and induction of beta -galactosidase expression. The nucleotide sequence of this clone revealed its identity to the 33-kDa farnesylated protein Pex19p/HK33/HsPxF/mPxF, which is essential for peroxisomal biogenesis (17-19, 21). The amino- and carboxyl-terminal halves of p19ARF were cloned into the Gal4BD vector. Pex19p, either full-length or carboxyl- but not amino-terminal, strongly activated the beta -galactosidase reporter, indicating that it is the carboxyl terminus of p19ARF that interacts with Pex1p (Fig. 1A). Pex19p and p19ARF interacted strongly in a mammalian two-hybrid assay (Fig. 1B). To further detect their interaction in mammalian cells, we transfected COS-7 cells with expression plasmids encoding tagged Pex19p and p19ARF and found that the proteins coimmunoprecipitated (Fig. 1C). GFP1-tesmin and MPD-myc were used as respective unrelated negative controls. As seen in Fig. 1C (left panel), GFP-Pex19p coprecipitated with p19ARF-myc (immunoprecipitated with anti-myc antibody) but not with MPD-myc or with isotype-matched control antibody (Fig. 1C, cf. lanes 1 and 4). GFP-tesmin (negative control) did not precipitate with p19ARF-myc. Furthermore, immunoprecipitation of hemagglutinin (HA)-tagged p19ARF from NIH-ARF cells with anti-HA tag antibody resulted in coprecipitation of a protein at ~35-kDa, along with several others including Mdm2 (22). It is likely that the 35-kDa p19ARF coprecipitate is Pex19p.


View larger version (53K):
[in this window]
[in a new window]
 
Fig. 1.   p19ARF interacts with Pex19p. A, activation of yeast two-hybrid beta - galactosidase reporter by Pex19p and either the full-length p19ARF or its carboxyl-terminal half. Yeast cells were transformed with plasmids encoding Pex19p and full-length (F), amino-terminal (N), or carboxyl-terminal (C) p19ARF. beta -Galactosidase (beta -Gal) activity was measured by liquid assay. B, activation of mammalian two-hybrid luciferase reporter by transfection of cDNAs encoding mouse Pex19p and p19ARF in COS-7 cells. C, in vivo coimmunoprecipitation of Pex19p and p19ARF. Cells were transfected with plasmids encoding a GFP-Pex19p fusion protein or GFP-tesmin (a negative control) and myc epitope-tagged p19ARF (p19ARF-myc) or MPD-myc (a negative control). Immunoprecipitation was performed with a polyclonal anti-myc antibody, and the myc immunocomplexes were analyzed for the presence of GFP-Pex19p or GFP-tesmin by Western blotting with a monoclonal anti-GFP antibody. GFP-Pex19p coprecipitated with p19ARF-myc (lane 1) but not in the absence of p19ARF-myc (lane 3), and not with MPD-myc (lanes 4 and 5) or control isotype-matched antibody (con.IgG). GFP-tesmin was not precipitated with p19ARF-myc. Input panel shows the signal from 10% of the lysate used for immunoprecipitation.

To determine whether Pex19p and p19ARF colocalize within intact cells, we visualized the proteins by immunostaining COS-7 (not shown) and NIH 3T3 cells transfected with tagged p19ARF and/or Pex19p. p19ARF localized mainly in the nucleolus, but there was some diffuse staining in the cytoplasm (Fig. 2A, a and b). Pex19p was seen only in the cytoplasm (Fig. 2A, c). Most notably, cells expressing both p19ARF-myc and GFP-Pex19p showed p19ARF in the cytoplasm in more than 90% of cells (Fig. 2A, d) where it colocalized with Pex19p (Fig. 2A, d-f) suggesting that the overexpression of Pex19p causes nuclear exclusion of p19ARF (Fig. 2A). As p19ARF has been shown to bind to and inactivate mdm2 in the nucleus (11, 16) resulting in activation of p53, we predicted that exclusion of p19ARF from the nucleus would lead to inactivation of p53 function via increased mdm2-mediated degradation.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 2.   Pex19p sequesters p19ARF in the cytoplasm and causes inactivation of p53 function. A, immunolocalization of p19ARF (a, b, and d) and Pex19p (c and e). NIH 3T3 cells were transfected with one (upper row) or two (lower row) plasmids encoding the proteins indicated and were stained with tag-specific antibodies. Pex19p was seen only in the cytoplasm (panels c and e) with or without p19ARF. p19ARF was localized in the nucleolus and cytoplasm in the absence (a and b) and in the cytoplasm only in the presence (d) of overexpressed Pex19p. B, NIH 3T3 cells transfected with increasing amounts of plasmid encoding V5-tagged p19ARF showed up-regulation of p53-dependent luciferase activity (an expected activity) (a). Cotransfection of plasmid encoding Pex19p with p19ARF blocked the p19ARF-induced up-regulation of p53-dependent reporter activity (b). The induction of p19ARF in NIH-ARF cells by ZnSO4 led to an increase in p53-dependent reporter activity. Expression of Pex19p resulted in a decrease in p53 function, whereas its antisense expression led to a dramatic increase (c). NIH 3T3 cells that lack expression of p19ARF did not show any effect of expression of Pex19p and its antisense construct on p53-dependent reporter activity (d).

NIH 3T3 cells lack endogenous p19ARF because of biallelic loss of the INK4a locus. As expected, transfection of these cells with p19ARF resulted in a dose-dependent increase in p53 activity (Fig. 2B, a). Cotransfections of Pex19p with p19ARF blocked p53 activation (Fig. 2B, b). We ruled out the possibility that p53 might be inactivated by direct interaction with Pex19p by performing in vivo coimmunoprecipitation of Pex19p and p53 wherein no Pex19p was seen to precipitate with p53 (data not shown). We next used stably transfected NIH 3T3 cells (NIH-ARF) that express exogenous HA-tagged p19ARF under the control of the heavy metal-inducible metallothionein promoter (22). The addition of 100 µM ZnSO4 to the culture medium resulted in the expression of HA-p19ARF (detectable by Western blotting) and a concurrent increase in p53-dependent luciferase reporter activity (Fig. 2B, c). NIH-ARF cells were stably transfected with expression plasmids encoding sense (S) and antisense (AS) His-tagged Pex19p protein and were selected in medium supplemented with zeocine (1 mg/ml). These derivatives were analyzed for endogenous p53 activity when cultured in the presence of increasing amounts of ZnSO4; 100 µM induced p19ARF expression detectable by Western blotting. As predicted and consistent with the results of transient transfections (Fig. 2B, b), Pex19p transfectants (NIH-ARF/Pex19p-S) showed down-regulation of p53 function and notably, the antisense derivative (NIH-ARF/Pex19p-AS) showed dramatic up-regulation (Fig. 2B, c). NIH 3T3 cells that lacked p19ARF did not show any effect of transfections of Pexp19-S and-AS constructs on p53-dependent reporter activity (Fig. 2B, d). Taken together these results demonstrated that: (i) an overexpression of Pex19p blocks p19ARF enhancement of p53-mediated transcriptional activation; (ii) this occurs most likely because of nuclear exclusion of p19ARF and abrogation of its interactions with Mdm2, resulting in active degradation of p53; and (iii) such an effect of Pex19p on the transcriptional activity of p53 is mediated by p19ARF.

We next analyzed the effect of Pex19p-p19ARF interactions on the expression of p21WAF1, a gene that is transactivated by p53. Induction of p19ARF led to up-regulation of p21WAF1 expression in NIH-ARF cells as has been described (22). Notably, Western blot analysis of p19ARF and Pex19p with respective tag-specific antibodies revealed that the induction of p19ARF led to stabilization of Pex19p (Fig. 3A, a). On the other hand, antisense derivatives of NIH-ARF/Pex19p had more p19ARF than sense derivatives when cultured in the presence of ZnSO4 for an equal time (Fig. 3A, a and b) suggesting that Pex19p may cause destabilization/degradation of p19ARF by a mechanism that remains to be defined. Accordingly, NIH-ARF/Pex19p antisense derivatives showed a high level of p21WAF1 expression, whereas Pex19p sense derivatives showed a lower level as compared with the control NIH-ARF cells (Fig. 3A, a). The data suggested that antisense Pex19p decreased the level of endogenous Pex19p, resulting in activation of the p19ARF-p53-p21WAF1 pathway. This interpretation was supported by the finding that transfection of the antisense construct into NIH-ARF cells that stably express His-tagged Pex19p resulted in decreased levels of His-Pex19p protein (Fig. 3A, c). We next studied the growth of NIH-ARF cells and their Pex19p sense and antisense derivatives for Pex19p expression when cultured with and without ZnSO4. As expected, the induction of p19ARF in NIH-ARF cells led to growth retardation (Fig. 3, B and C). Increased expression of Pex19p decreased p19ARF-induced growth retardation (Fig. 3, B and C), seemingly because of inactivation of the p53 function via nuclear exclusion of p19ARF by Pex19p, as demonstrated above. NIH-ARF expressing antisense Pex19p showed severe retardation of growth, exhaustion of their replicative potential, and a senescence-like morphology (Fig. 3, B and C). On the other hand, growth of NIH 3T3 cells that lack p19ARF expression was not affected by transfections of Pex19p-S and -AS, constructs demonstrating that the effect was mediated by p19ARF-Pex19p interactions (Fig. 3C and data not shown). This data implies that p19ARF function is blocked, at least in part, by its interactions with endogenous Pex19p, and abrogation of these interactions by antisense expression of Pex19p led to activation of p19ARF-p53-p21WAF1 pathway and execution of a senescence-like growth arrest.


View larger version (53K):
[in this window]
[in a new window]
 
Fig. 3.   Down-regulation of p19ARF-p53-p21WAF1 pathway by Pex19p. Expression of antisense Pex19p led to activation of the p19ARF-p53-p21WAF1 pathway and induction of a senescence-like phenotype. A, NIH-ARF cells were stably transfected with plasmids encoding sense (Pex19p-S) and antisense (Pex19p-AS) His-tagged Pex19p (His-Pex19p). A high level of expression of Pex19p was seen when cells were induced for p19ARF expression (a). On the contrary, p19ARF was less in NIH-ARF/Pex19p-S cells as compared with either control NIH-ARF or NIH-ARF/Pex19p-AS cells (a and b). Induction of p21WAF1 by p19ARF was less in NIH-ARF/Pex19p-S and more in NIH-ARF/Pex19p-AS as compared with the NIH-ARF (a). Antisense expression of Pex19p neutralized the effects of expressing His-Pex19p in NIH-ARF/Pex19p-S cells (c). B, growth characteristics of NIH-ARF cells stably transfected with Pex19p or its antisense expression construct. Cells maintained in the presence (+) or absence (-) of 100 µM ZnSO4 were fixed, stained with Giemsa and photographed just after the addition of ZnSO4 (Day 0) or after 3 days of culture (Day 3). Note the senescence-like morphology of NIH-ARF/Pex19p-AS cells when cultured in the presence of ZnSO4. C, equal numbers of cells of the types indicated were plated and cultured with (+) or without (-) ZnSO4. Cells were counted in six independent fields after 3 days of culture. Error bars represent standard deviations from six experiments.

As p19ARF and its human homologue p14ARF are important mediators of cellular senescence (5, 6, 9, 23, 24), understanding its precise mechanism of action and how it is controlled is clearly important. p53 has a central role in many aspects of the cell's response to its environment and control of proliferation (25), in part because of transcriptional control of effectors such as p21WAF1; understanding the factors that regulate its activity is also of critical importance. We have described here a novel mechanism of down-regulation of the p19ARF-p53-p21WAF1 pathway.

    FOOTNOTES

** To whom correspondence should be addressed. Tel.: 81-298-30-6211; Fax: 81-298-30-6270; E-mail: renu@cimmed.com.

Published, JBC Papers in Press, March 19, 2001, DOI 10.1074/jbc.C100011200

    ABBREVIATIONS

The abbreviations used are: GFP, green fluorescent protein; HA, hemagglutinin; MPD, mevalonate pyrophosphate decarbonylase; ARF, alternative reading frame.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

1. Quelle, D. E., Zindy, F., Ashmun, R. A., and Sherr, C. J. (1995) Cell 83, 993-1000[Medline] [Order article via Infotrieve]
2. Serrano, M., Lee, H., Chin, L., Cordon-Cardo, C., Beach, D., and DePinho, R. A. (1996) Cell 85, 27-37[Medline] [Order article via Infotrieve]
3. Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., and Sherr, C. J. (1997) Cell 91, 649-659[Medline] [Order article via Infotrieve]
4. Vogt, M., Haggblom, C., Yeargin, J., Christiansen-Weber, T., and Haas, M. (1998) Cell Growth & Differ. 9, 139-146[Abstract]
5. Huschtscha, L. I., and Reddel, R. R. (1999) Carcinogenesis 20, 921-926[Abstract/Free Full Text]
6. Carnero, A., Hudson, J. D., Price, C. M., and Beach, D. H. (2000) Nat. Cell Biol. 2, 148-155[CrossRef][Medline] [Order article via Infotrieve]
7. Jacobs, J. J., Kieboom, K., Marino, S., DePinho, R. A., and van Lohuizen, M. (1999) Nature 397, 164-168[CrossRef][Medline] [Order article via Infotrieve]
8. Sharpless, N. E., and DePinho, R. A. (1999) Curr. Opin. Genet. Dev. 9, 22-30[CrossRef][Medline] [Order article via Infotrieve]
9. Kamijo, T., van de Kamp, E., Chong, M. J., Zindy, F., Diehl, J. A., Sherr, C. J., and McKinnon, P. J. (1999) Cancer Res. 59, 2464-2469[Abstract/Free Full Text]
10. Stott, F. J., Bates, S., James, M. C., McConnell, B. B., Starborg, M., Brookes, S., Palmero, I., Ryan, K., Hara, E., Vousden, K. H., and Peters, G. (1998) EMBO J. 17, 5001-5014[Abstract/Free Full Text]
11. Kamijo, T., Weber, J. D., Zambetti, G., Zindy, F., Roussel, M. F., and Sherr, C. J. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 8292-8297[Abstract/Free Full Text]
12. Zhang, Y., Xiong, Y., and Yarbrough, W. G. (1998) Cell 92, 725-734[Medline] [Order article via Infotrieve]
13. Honda, R., and Yasuda, H. (1999) EMBO J. 18, 22-27[Abstract/Free Full Text]
14. Weber, J. D., Taylor, L. J., Roussel, M. F., Sherr, C. J., and Bar-Sagi, D. (1999) Nat. Cell Biol. 1, 20-26[CrossRef][Medline] [Order article via Infotrieve]
15. Weber, J. D., Kuo, M. L., Bothner, B., DiGiammarino, E. L., Kriwacki, R. W., Roussel, M. F., and Sherr, C. J. (2000) Mol. Cell. Biol. 20, 2517-2528[Abstract/Free Full Text]
16. Tao, W., and Levine, A. J. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 6937-6941[Abstract/Free Full Text]
17. Braun, A., Kammerer, S., Weissenhorn, W., Weiss, E. H., and Cleve, H. (1994) Gene 146, 291-295[Medline] [Order article via Infotrieve]
18. Kammerer, S., Arnold, N., Gutensohn, W., Mewes, H. W., Kunau, W. H., Hofler, G., Roscher, A. A., and Braun, A. (1997) Genomics 45, 200-210[CrossRef][Medline] [Order article via Infotrieve]
19. Gotte, K., Girzalsky, W., Linkert, M., Baumgart, E., Kammerer, S., Kunau, W. H., and Erdmann, R. (1998) Mol. Cell. Biol. 18, 616-628[Abstract/Free Full Text]
20. Louvet, O., Doignon, F., and Crouzet, M. (1997) BioTechniques 23, 816-818[Medline] [Order article via Infotrieve]
21. Fujiki, Y. (2000) FEBS Lett. 476, 42-46[CrossRef][Medline] [Order article via Infotrieve]
22. Kurokawa, K., Tanaka, T., and Kato, J. (1999) Oncogene 18, 2718-2727[CrossRef][Medline] [Order article via Infotrieve]
23. Dimri, G. P., Itahana, K., Acosta, M., and Campisi, J. (2000) Mol. Cell. Biol. 20, 273-285[Abstract/Free Full Text]
24. Jacobs, J. J., Scheijen, B., Voncken, J. W., Kieboom, K., Berns, A., and van Lohuizen, M. (1999) Genes Dev. 13, 2678-2690[Abstract/Free Full Text]
25. Levine, A. J. (1997) Cell 88, 323-331[Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.